Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28.

Slides:



Advertisements
Similar presentations
Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.
Advertisements

Lancet : doi: /S (08)60104-X Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from.
Cholesterol Treatment Trialists’ (CTT) Collaboration. Lancet 2010;epub 9 Nov.
Number of participants with diabetes by trial Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:
Baseline characteristics and eligibility criteria of participating trials Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta- analysis of the randomised trials The Lancet Volume 386, Issue 10001,
Volume 376, Issue 9753, Pages (November 2010)
Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of.
Food systems, nutrition, health and the environment
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials  Cholesterol.
Predicted 5-year benefits of LDL cholesterol reductions with statin treatment at different levels of risk. (A) Major vascular events, and (B) vascular.
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.
Volume 376, Issue 9734, Pages (July 2010)
Volume 388, Issue 10059, Pages (November 2016)
Total and cause-specific mortality before and after the onset of the Greek economic crisis: an interrupted time-series analysis  Ioannis Laliotis, PhD,
The commercial determinants of health
Helen Cox, Mark P Nicol  The Lancet Infectious Diseases 
Meta-analysis of randomised controlled trials
Volume 388, Issue 10059, Pages (November 2016)
Author gender in The Lancet journals
The impact of megacities on health: preparing for a resilient future
Volume 389, Issue 10076, Pages (April 2017)
Volume 376, Issue 9734, Pages (July 2010)
Charity begins at home in global health research funding
Threats to human health by great ocean garbage patches
Volume 388, Issue 10052, Pages (October 2016)
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
Closed-loop insulin delivery in inpatients with type 2 diabetes: a randomised, parallel- group trial  Hood Thabit, PhD, Sara Hartnell, BSc, Janet M Allen,
Aspirin in the prevention of cancer – Author's reply
Do air quality alerts benefit public health? New evidence from Canada
Nicola Low, Joost H Smid  The Lancet Public Health 
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials  Cholesterol.
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta- analysis of individual participant data from randomised trials 
Prof Seena Fazel, MD, Taanvi Ramesh, MSc, Prof Keith Hawton, FMedSci 
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.
Effective cross-sector collaborations create sustainability
Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3·6 million adults in the UK  Krishnan Bhaskaran, PhD,
Effect of diabetes duration and glycaemic control on 14-year cause-specific mortality in Mexican adults: a blood-based prospective cohort study  William.
Meta-analysis of randomised controlled trials
Arnaud Chiolero  The Lancet Public Health 
Jonathan Broad, Matthew D Snape  The Lancet Public Health 
Volume 386, Issue 10001, Pages (October 2015)
Low-level lead exposure and mortality in US adults: a population-based cohort study  Prof Bruce P Lanphear, MD, Stephen Rauch, MPH, Peggy Auinger, MS,
Food systems, nutrition, health and the environment
Mapping university global health partnerships
Volume 386, Issue 10001, Pages (October 2015)
MRC/BHF Heart Protection Study
Volume 376, Issue 9753, Pages (November 2010)
Volume 371, Issue 9627, Pages (May 2008)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials  Cholesterol.
Volume 382, Issue 9894, Pages (August 2013)
C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study  Heart Protection.
Volume 375, Issue 9719, Pages (March 2010)
Muh Geot Wong, Vlado Perkovic  The Lancet Diabetes & Endocrinology 
Thank you to our diverse (but not diverse enough) reviewers
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
Volume 6, Issue 3, Pages (March 2019)
Matthieu J Guitton  The Lancet Planetary Health 
Spatial lifecourse epidemiology
Buyun Liu, Yangbo Sun, Wei Bao  The Lancet Planetary Health 
The Lancet Diabetes & Endocrinology
Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised.
Improving management of neonatal infections
Jeffrey T Howard, Alexis R Santos-Lozada  The Lancet Planetary Health 
Refining treatment choices for ADHD
Volume 6, Issue 7, Pages (July 2019)
Institutional challenges to achieving health equity in Ecuador
Sickle cell disease: a new era
Trends in temperature-related age-specific and sex-specific mortality from cardiovascular diseases in Spain: a national time-series analysis  Hicham Achebak,
Presentation transcript:

Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials    The Lancet Diabetes & Endocrinology  Volume 4, Issue 10, Pages 829-839 (October 2016) DOI: 10.1016/S2213-8587(16)30156-5 Copyright © 2016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Terms and Conditions

Figure 1 Effects on major vascular events per mmol/L reduction in LDL cholesterol, by baseline renal function Data for participants with missing creatinine values at baseline are included in totals. Black squares and horizontal lines represent 99% CIs. White diamonds represent 95% CIs. Vertical dotted line represents overall RR for each outcome. eGFR=estimated glomerular filtration rate. RR=rate ratio. The Lancet Diabetes & Endocrinology 2016 4, 829-839DOI: (10.1016/S2213-8587(16)30156-5) Copyright © 2016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Terms and Conditions

Figure 2 Effects on major coronary events per mmol/L reduction in LDL cholesterol, by baseline renal function Data for participants with missing creatinine values at baseline are included in totals. Black squares and horizontal lines represent 99% CIs. White diamonds represent 95% CIs. Vertical dotted line represents overall RR for each outcome. eGFR=estimated glomerular filtration rate. RR=rate ratio. The Lancet Diabetes & Endocrinology 2016 4, 829-839DOI: (10.1016/S2213-8587(16)30156-5) Copyright © 2016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Terms and Conditions

Figure 3 Effects on cause-specific mortality per mmol/L reduction in LDL cholesterol, by baseline renal function Data for participants with missing creatinine values at baseline are included in totals. Black squares and horizontal lines represent 99% CIs. White diamonds represent 95% CIs. Vertical dotted line represents overall RR for each outcome. eGFR=estimated glomerular filtration rate. RR=rate ratio.*Includes 583 deaths from an unknown cause in the statin or more intensive regimen group and 653 deaths from an unknown cause in the control or less intensive regimen group. The Lancet Diabetes & Endocrinology 2016 4, 829-839DOI: (10.1016/S2213-8587(16)30156-5) Copyright © 2016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Terms and Conditions